Variable | Traditional DMARDs | Biological DMARDs | Combination group |
---|---|---|---|
Patient (n) | 1184 | 419 | 774 |
Age (year) | 54.2±12.3 | 51.4±13.4 | 50.5±13.4 |
Female (%) | 73.5 | 74.0 | 72.3 |
Duration of rheumatoid arthritis (years) | 2.8±3.5 | 2.1±3.2 | 1.8±3.1 |
Rheumatoid factor positivity (%) | 73.3 | 76.6 | 73.0 |
Disease activity score 28 | 6.7±1.0 | 6.3±1.2 | 6.2±1.2 |
Simplified Disease Activity Index | 47.1±14.9 | 43.6±15.4 | 39.6±14.4 |
Clinical Disease Activity Index | 43.4±13.4 | 40.7±13.9 | 36.8±13.2 |
SJC (0–28) | 14.5±6.4 | 13.3±6.18 | 10.6±5.6 |
Tender joint count (0–28) | 16.3±6.9 | 15.2±7.07 | 14.0±6.7 |
CRP | 3.7±4.0 | 2.9±3.7 | 2.8±3.4 |
Erythrocyte sedimentation rate | 47.7±25.0 | 38.4±25.7 | 41.3±27.0 |
Patient global assessment | 62.7±20.2 | 61.0±21.6 | 59.7±24.5 |
Evaluator global assessment | 63.0±16.5 | 60.1±19.6 | 62.1±20.0 |
Health Assessment Questionnaire | 1.49±0.66 | 1.48±0.66 | 1.45±0.67 |
Total Sharp/van der Heijde Score | 22.4±31.0 | 18.4±30.5 | 16.8±25.6 |
Data are shown as mean±SD unless otherwise indicated.
DMARDs, disease-modifying antirheumatic drugs.